PDCD1 and pancreatic neoplasm: One mouse experiment of pancreatic cancer confirmed that the combination PD-1 inhibitors and OX40 agonists reduced the proportion of Treg and exhausted T cells, and increased the number of CD4+ and CD8+ T cells in pancreatic tumors [21].